However, in the off-tumor condition, the concentrations of IFN-γ, IL-6, and TNF-α released from MB2033-treated hPBMCs were lower (data not shown) than those released following the treatment of aldesleukin or αPD-L1 × non-α IL-2v (Fig. 5c). The gene discussed is IL2; the disease is neoplasm.